{"id": 779028763795415040, "geo": null, "lang": "en", "text": "RT @RareDR: Teva's Tardive Dyskinesia Treatment Shows Positive Results in Phase 3 Trial https://t.co/3RBrITK8GK", "user": {"id": 183626808, "url": "http://t.co/PlXHLByVXo", "lang": "en", "name": "Teva Pharmaceuticals", "id_str": "183626808", "entities": {"url": {"urls": [{"url": "http://t.co/PlXHLByVXo", "indices": [0, 22], "display_url": "tevausa.com", "expanded_url": "http://www.tevausa.com"}]}, "description": {"urls": [{"url": "https://t.co/gsGkRP8J3A", "indices": [136, 159], "display_url": "ow.ly/UZcKg", "expanded_url": "http://ow.ly/UZcKg"}]}}, "location": "United States", "verified": false, "following": true, "protected": false, "time_zone": null, "created_at": "Fri Aug 27 13:45:33 +0000 2010", "utc_offset": null, "description": "Official Teva US Twitter feed. We don't just make medicines, we make a difference in people's lives. Managed by Corp Comms. Guidelines: https://t.co/gsGkRP8J3A", "geo_enabled": false, "screen_name": "TevaUSA", "listed_count": 108, "friends_count": 1167, "is_translator": false, "notifications": false, "statuses_count": 1799, "default_profile": false, "followers_count": 5772, "translator_type": "none", "favourites_count": 855, "profile_image_url": "http://pbs.twimg.com/profile_images/1114240566001315840/wwBtyZu1_normal.png", "profile_banner_url": "https://pbs.twimg.com/profile_banners/183626808/1517338835", "profile_link_color": "94D487", "profile_text_color": "000000", "follow_request_sent": false, "contributors_enabled": false, "has_extended_profile": false, "default_profile_image": false, "is_translation_enabled": false, "profile_background_tile": false, "profile_image_url_https": "https://pbs.twimg.com/profile_images/1114240566001315840/wwBtyZu1_normal.png", "profile_background_color": "94D487", "profile_sidebar_fill_color": "000000", "profile_background_image_url": "http://abs.twimg.com/images/themes/theme1/bg.png", "profile_sidebar_border_color": "000000", "profile_use_background_image": false, "profile_background_image_url_https": "https://abs.twimg.com/images/themes/theme1/bg.png"}, "place": null, "id_str": "779028763795415040", "source": "<a href=\"http://twitter.com/download/iphone\" rel=\"nofollow\">Twitter for iPhone</a>", "entities": {"urls": [{"url": "https://t.co/3RBrITK8GK", "indices": [88, 111], "display_url": "shar.es/1x52pN", "expanded_url": "https://shar.es/1x52pN"}], "symbols": [], "hashtags": [], "user_mentions": [{"id": 547834727, "name": "MDMagazine: Rare Diseases", "id_str": "547834727", "indices": [3, 10], "screen_name": "RareDR"}]}, "favorited": false, "retweeted": false, "truncated": false, "created_at": "Thu Sep 22 18:45:05 +0000 2016", "coordinates": null, "contributors": null, "retweet_count": 1, "favorite_count": 0, "is_quote_status": false, "retweeted_status": {"id": 778969196764008449, "geo": null, "lang": "en", "text": "Teva's Tardive Dyskinesia Treatment Shows Positive Results in Phase 3 Trial https://t.co/3RBrITK8GK", "user": {"id": 547834727, "url": "https://t.co/BR6R6srgZv", "lang": "en", "name": "MDMagazine: Rare Diseases", "id_str": "547834727", "entities": {"url": {"urls": [{"url": "https://t.co/BR6R6srgZv", "indices": [0, 23], "display_url": "raredr.com", "expanded_url": "http://www.raredr.com"}]}, "description": {"urls": []}}, "location": "", "verified": false, "following": false, "protected": false, "time_zone": null, "created_at": "Sat Apr 07 19:04:35 +0000 2012", "utc_offset": null, "description": "Providing breaking news, patient stories and FDA updates, specific to those within the rare disease community. Now a part of @mdmagazine.", "geo_enabled": true, "screen_name": "RareDR", "listed_count": 310, "friends_count": 1296, "is_translator": false, "notifications": false, "statuses_count": 18695, "default_profile": false, "followers_count": 14317, "translator_type": "none", "favourites_count": 1563, "profile_image_url": "http://pbs.twimg.com/profile_images/1112779374397480960/LtbsCGJ6_normal.png", "profile_banner_url": "https://pbs.twimg.com/profile_banners/547834727/1532455979", "profile_link_color": "0D5B92", "profile_text_color": "333333", "follow_request_sent": false, "contributors_enabled": false, "has_extended_profile": false, "default_profile_image": false, "is_translation_enabled": false, "profile_background_tile": true, "profile_image_url_https": "https://pbs.twimg.com/profile_images/1112779374397480960/LtbsCGJ6_normal.png", "profile_background_color": "EDECE9", "profile_sidebar_fill_color": "FFFFFF", "profile_background_image_url": "http://abs.twimg.com/images/themes/theme13/bg.gif", "profile_sidebar_border_color": "000000", "profile_use_background_image": true, "profile_background_image_url_https": "https://abs.twimg.com/images/themes/theme13/bg.gif"}, "place": null, "id_str": "778969196764008449", "source": "<a href=\"http://twitter.com\" rel=\"nofollow\">Twitter Web Client</a>", "entities": {"urls": [{"url": "https://t.co/3RBrITK8GK", "indices": [76, 99], "display_url": "shar.es/1x52pN", "expanded_url": "https://shar.es/1x52pN"}], "symbols": [], "hashtags": [], "user_mentions": []}, "favorited": false, "retweeted": false, "truncated": false, "created_at": "Thu Sep 22 14:48:23 +0000 2016", "coordinates": null, "contributors": null, "retweet_count": 1, "favorite_count": 2, "is_quote_status": false, "possibly_sensitive": false, "in_reply_to_user_id": null, "in_reply_to_status_id": null, "in_reply_to_screen_name": null, "in_reply_to_user_id_str": null, "in_reply_to_status_id_str": null}, "possibly_sensitive": false, "in_reply_to_user_id": null, "in_reply_to_status_id": null, "in_reply_to_screen_name": null, "in_reply_to_user_id_str": null, "in_reply_to_status_id_str": null}